Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Combination Regimens in NASH
NCT02781584Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of selonsertib, firsocostat and cilofexor in Nonalcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) (13 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events at 8 weeks, Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events at 8 weeks and 1 more. Started Jun 2016; status: completed.
02
Drugs
selonsertibfirsocostatcilofexor
03
Conditions
Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02781584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781584.